Advertisement

Alternative Modes of Administration of Salmon Calcitonin in Paget’s Disease of Bone

  • Charles Nagant de Deuxchaisnes
  • Jean-Pierre Devogelaer

Abstract

Calcitonin (CT) has an antiosteolytic action1 with a clear therapeutic role in the treatment of Paget’s disease as well as the prevention and treatment of osteoporosis.2–4 The parenteral mode of administration of CT is a deterrent to its use in both Paget’s disease and osteoporosis and is even less unacceptable in the prevention of osteoporosis. The advent of a nasal spray of salmon CT (SCT), which was studied in human volunteers for the first time in our unit in May 1983 and shown to have bioactivity,5,6 has opened a new frontier in the therapeutic application of this peptide. Although the main purposes of intranasal insufflation of SCT (INSCT) are prevention and treatment of osteoporosis, Paget’s disease of bone remains the model by which it is possible to judge its effectiveness, by monitoring parameters of bone turnover. This is an exceedingly reliable method to test the efficacy of INSCT and allows comparison of different doses as well as different forms of INSCT (with or without absorption promoters).

Keywords

Nasal Mucosa Nasal Spray Alternative Mode Alkaline Phosphatase Level Salmon Calcitonin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Nagant de Deuxchaisnes C: Calcitonin in the treatment of Paget’s disease. Triangle 1983; 22: 103–128.Google Scholar
  2. 2.
    Nagant de Deuxchaisnes C: Use of calcitonin in the treatment of postmenopausal osteoporosis, In DeLuca HF, Mazess R (eds.): Osteoporosis. Physiological Basis, Assessment, and Treatment. New York, Elsevier, 1990, pp 247–258.Google Scholar
  3. 3.
    Nagant de Deuxchaisnes C: Medical management of Paget’s disease, In DeGroot LJ (ed.): Endocrinology, 2nd ed. Vol 2. Philadelphia, WB Saunders, 1989, pp 1211–1244.Google Scholar
  4. 4.
    Nagant de Deuxchaisnes C, Devogelaer JP: Surveillance et suivi à long terme de la maladie osseuse de Paget (except English summary), In Simon L, Sebert JL, Hérisson C (eds.): La Maladie Osseuse de Paget. Actualités. Paris, Masson, 1989, pp 257–273.Google Scholar
  5. Nagant de Deuxchaisnes C, Devogelaer JP, Huaux JP, et al: Effect of a nasal spray of salmon calcitonin in normal subjects and in patients with Paget’s disease of bone, In Pecile A (ed.): Calcitonin 1984. Amsterdam, Elsevier Science Publishers BV, 1985, pp 329–343.Google Scholar
  6. 6.
    Nagant, de Deuxchaisnes C, Devogelaer JP, Huaux JP et al: New modes of administration of salmon calcitonin in Paget’s disease. Nasal spray and suppository. Clin Orthop 1987; 217: 56–71.Google Scholar
  7. 7.
    Pontiroli AE, Calderara A, Pozza G: Intranasal drug delivery: Potential advantages and limitation from a clinical pharmacokinetic perspective. Clin Pharmacokinet 1989; 17: 299–307.PubMedCrossRefGoogle Scholar
  8. 8.
    Ziegler R, Holz G, Raue F, Streibl W: Nasal application of human calcitonin in Paget’s disease of bone, In Maclntyre I, Szelke M (eds.): Molecular Endocrinology. Amsterdam, Elsevier/North Holland Biomedical Press, 1979, pp 293–300.Google Scholar
  9. 9.
    Guttman S: Chemistry and structure-activity relationship of natural and synthetic calcitonins, In Pecile A (ed.): Calcitonin 1980. Amsterdam, Excerpta Medica, 1981, pp 11–24.Google Scholar
  10. 10.
    Singer FR, Rude RK, Mills BG: Studies of the treatment and aetiology of Paget’s disease of bone, In Maclntyre I (ed.): Human Calcitonin and Paget’s disease. Bern, Hans Huber Publishers, 1977, pp 93–110.Google Scholar
  11. 11.
    Marx SJ, Woodard CJ, Aurbach GD: Calcitonin receptors of kidney and bone. Science 1972; 178: 999–1000.PubMedCrossRefGoogle Scholar
  12. 12.
    Pontiroli AE, Alberetto M, Pozza G: Intranasal calcitonin and plasma calcium concentrations in normal subjects. Br Med J 1985; 290: 1390–91.CrossRefGoogle Scholar
  13. 13.
    Russell RGG, Smith R, Preston C, et al: Diphosphonates in Paget’s disease. Lancet 1974; 1: 894–898.PubMedGoogle Scholar
  14. 14.
    Levy F, Muff R, Dotti-Sigrist S, et al: Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of Paget’s disease. J Clin Endocrinol Metab 1988; 67: 541–45.PubMedCrossRefGoogle Scholar
  15. 15.
    Duchateau GSMJE, Zuidema J, Merkus FWHM: Bile salts and intranasal drug absorption. Int J Pharm 1986; 31: 193–199.CrossRefGoogle Scholar
  16. 16.
    Nagant, de Deuxchaisnes C, Devogelaer JP, Huaux JP et al: Intranasal calcitonin and plasma calcium concentrations. Br Med J 1985; 291: 544–545.CrossRefGoogle Scholar
  17. 17.
    Gagel RF, Logan C, Mallette LE: Treatment of Paget’s disease of bone with salmon calcitonin nasal spray. J Am Geriatr Soc 1988; 36: 1011–1014.Google Scholar
  18. 18.
    D’Agostino HR, Barnett CA, Zielinski XJ, Gordan GS: Intranasal salmon calcitonin treatment of Paget’s disease of bone. Clin Orthop 1988; 230: 223–228.PubMedGoogle Scholar
  19. 19.
    O’Doherty DP, Bickerstaff DR, McCloskey EV, et al: A comparison of the acute effects of subcutaneous and intranasal calcitonin. Clin Sci 1990; 78: 215–219.PubMedGoogle Scholar
  20. 20.
    Thamsborg G, Storm TL, Brinch E, et al: The effect of different doses of nasal salmon calcitonin on plasma cyclic AMP and serum ionized calcium. Calcif Tissue Int 1990; 46: 5–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Pun KK, Chan LWL, Lau P, et al: Absorption of intranasal salmon calcitonin in normal subjects and hypogonadic men. Calcif Tissue Int 1990; 46: 130–132.PubMedCrossRefGoogle Scholar
  22. 22.
    Nagant de Deuxchaisnes C, Devogelaer JP: Alternative routes of administration of salmon calcitonin, In Mazzuoli GF (ed.): Calcitonin ′88. Milan, Esi Stampa Medica SpA, 1989, pp 87–98.Google Scholar
  23. 23.
    Nagant, de Deuxchaisnes C, Maldague B, Malghem J et al: The action of the main therapeutic regimes on Paget’s disease of bone, with a note on the effect of vitamin D deficiency. Arthritis Rheum 1980; 23: 1215–1234.CrossRefGoogle Scholar
  24. 24.
    Maldague B, Malghem J: Dynamic radiologic patterns of Paget’s disease of bone. Clin Orthop 1987; 217: 126–151.PubMedGoogle Scholar
  25. 25.
    Reginster JY, Jeugmans-Huynen AM, Albert A, et al: One year’s treatment of Paget’s disease of bone by synthetic salmon calcitonin as a nasal spray. J Bone Min Res 1988; 3: 249–252.CrossRefGoogle Scholar
  26. 26.
    Reginster JY, Franchimont P: Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection. Clin Exp Rheumatol 1985; 3: 155–157.PubMedGoogle Scholar
  27. 27.
    Eisinger J: Action de la calcitonine en spray nasal chez les pagétiques. Lyon Mediter Med 1985; 221: 9631–9634.Google Scholar
  28. 28.
    Eisinger J: Tolérance clinique de la calcitonine en fonction du mode d’administration: Intérêt des formes non injectables. Rev Rhum Mal Osteoartic 1987; 54: 65–67.PubMedGoogle Scholar
  29. 29.
    Gennari C, Chierichetti SM, Vibelli C, et al: Acute effects of salmon, human and porcine calcitonin on plasma calcium and cyclic AMP levels in man. Curr Ther Res 1981; 30: 1024–1032.Google Scholar
  30. 30.
    Maclntyre I, Stevenson JC, Whitehead MI, et al: Calcitonin for prevention of postmenopausal bone loss. Lancet 1988; 1: 900–901.CrossRefGoogle Scholar
  31. 31.
    Langer B, Peytremann A, Rufener C, Jenny M: Effets comparés de l’administration d’une dose unique de calcitonine synthétique (de type humain et de type saumon), chez l’homme normal et les sujets atteints de maladie de Paget ou d’hypercalcémie. Schweiz Med Wochenschr 1971; 101: 69–80.PubMedGoogle Scholar
  32. 32.
    Blanc D, Chapuy MC, Meunier P: Evaluation de l’activité ostéaclastique par le test d’hypocalcémie provoquée par la calcitonine de saumon. Nouv Presse Med 1977; 6: 2489–2494.PubMedGoogle Scholar
  33. 33.
    Fournié A, Valverde C, Tap G, et al: Test d’hypocalcémie aiguë à la calcitonine de porc et de saumon. Rev Rhum Mal Osteoartic 1977; 44: 91–98.PubMedGoogle Scholar
  34. 34.
    Buclin T, Randin JP, Jacquet AF, et al: The effect of rectal and nasal administration of salmon calcitonin in normal subjects. Calcif Tissue Int 1987; 41: 252–258.PubMedCrossRefGoogle Scholar
  35. 35.
    Kurose H, Seino Y, Shima M, et al: Intranasal absorption of salmon calcitonin. Calcif Tissue Int 1987; 41: 249–251.PubMedCrossRefGoogle Scholar
  36. 36.
    Vega E, Gonzales D, Ghiringielli G, Mautalen C: Acute effect of the intranasal administration of salmon calcitonin in osteoporotic women. Bone Miner 1989; 7: 267–273.PubMedCrossRefGoogle Scholar
  37. 37.
    Reginster JY, Denis D, Albert A, Franchimont P: Assessment of the biological effectiveness of nasal synthetic salmon calcitonin (SSCT) by comparison with intramuscular (I.M.) or placebo injection in normal subjects. Bone Miner 1987; 2: 133–140.PubMedGoogle Scholar
  38. 38.
    Krane SM, Harris ED Jr, Singer FR, Potts JT Jr: Acute effects of calcitonin on bone formation in man. Metabolism 1973; 22: 51–58.PubMedCrossRefGoogle Scholar
  39. 39.
    Gonzales D, Vega E, Ghiringhelli G, Mautalen C: Comparison of the acute effect of the intranasal and intramuscular administration of salmon calcitonin in Paget’s disease. Calcif Tissue Int 1987; 41: 313–315.CrossRefGoogle Scholar
  40. 40.
    Eisinger J: Comparison de l’effet hypocalcémiant immédiat de la calcitonine de saumon par voie veineuse et par voie nasale. Rev Rhum Mal Osteoartic 1985; 52: 195.PubMedGoogle Scholar
  41. 41.
    Tarquini B, Cavallini V, Cariddi A, et al: Prominent circadian absorption of intranasal salmon calcitonin (SCT) in healthy subjects. Chronobiologia 1988; 5: 149–152.CrossRefGoogle Scholar
  42. 42.
    Elomaa I, Azria M, Attinger M, Bleicher M: Pilot evaluation of the hypocalcemic effect of intranasal salmon calcitonin. Calcif Tissue Int 1985;37 (suppl):Abstract 383.Google Scholar
  43. 43.
    Sjöbeig HE, Toning O: Effect of nasal calcitonin in mild primary hyperparathyroidism. J Bone Min Res 1986;l(suppl 1): abstract 369.Google Scholar
  44. 44.
    Wallach S: Comparative effects of salmon, human and eel calcitonins on skeletal turn-over in human disease, in Gennari C, Segre G (eds.): The Effects of Calcitonin in Man. Milan, Masson Italia Editori, 1983, pp 141–151.Google Scholar
  45. 45.
    Hosking DJ: Practical implications of calcitonin antigenicity. In Gennari C, Segre G (eds.): The Effects of Calcitonin in Man. Milan, Masson Italia Editori, 1983, pp 67–74.Google Scholar
  46. 46.
    Singer FR, Rude RK, Mills BG: Studies of the treatment and aetiology of Paget’s disease of bone. In Maclntyre I (ed.): Human Calcitonin and Paget’s Disease. Bern, Hans Huber Publishers, 1977, pp 93–110.Google Scholar
  47. 47.
    Avramides A, Flores A, DeRose J, Wallach S: Treatment of Paget’s disease of bone with once a week injections of salmon calcitonin. Brit Med J 1975; 3: 632.PubMedCrossRefGoogle Scholar
  48. 48.
    Wallach S: Discussion after Singer et al.52 Google Scholar
  49. 49.
    Evans IMA: Human calcitonin in the treatment of Paget’s disease: Long-term trials, in Maclntyre I (ed.): Human Calcitonin and Paget’s Disease. Bern, Hans Huber Publishers, 1977; 111–123.Google Scholar
  50. 50.
    Bordier PJ, Woodhouse NJY, Maris PJ, et al: Treatment of Paget’s disease with human calcitonin: Histological evidence of healing. Eur J Clin Invest 1972; 2: 275.Google Scholar
  51. 51.
    Palmieri GMA, Pitcock JA, Brown P, et al: Effect of calcitonin and vitamin D in osteoporosis. Calcif Tissue Int 1989; 45: 137–141.PubMedCrossRefGoogle Scholar
  52. 52.
    Singer FR, Fredericks RS, Minkin C: Salmon calcitonin therapy for Paget’s disease of bone: The problem of acquired clinical resistance. Arthritis Rheum 1980; 23: 1148–1153.PubMedCrossRefGoogle Scholar
  53. 53.
    Muff R, Dambacher MA, Perrenoud A, et al: Efficacy of intranasal human calcitonin in patients with Paget’s disease refractory to salmon calcitonin. Am J Med 1990; 89: 181–184.PubMedCrossRefGoogle Scholar
  54. 54.
    Reginster JY, Aimer S, Gaspar S, et al: Hypocalcémie induite chez le sujet pagétique par la calcitonine salmine nasale: Effets des anticorps anticalcitonine salmine. Rev Rhum Mal Osteoartic 1989; 56 (7): 563–567.PubMedGoogle Scholar
  55. 55.
    Reginster JY, Gennari C, Mautalen C, et al: Influence of specific anti-salmon calcitonin antibodies on biological effectiveness of nasal salmon calcitonin in Paget’s disease of bone. Scand J Rheumatol 1990; 19: 83–86.PubMedCrossRefGoogle Scholar
  56. 56.
    Grauer A, Raue F, Schneider HG, et al: In vitro detection of neutralizing antibodies after treatment of Paget’s disease of bone with nasal salmon calcitonin. J Bone Miner Res 1990; 5: 387–391.PubMedCrossRefGoogle Scholar
  57. 57.
    Rojanasathit D, Rosenberg E, Haddad JG Jr. Paget’s bone disease: Response to human calcitonin in patients resistant to salmon calcitonin. Lancet 1974; 2: 1412–1415.PubMedCrossRefGoogle Scholar
  58. 58.
    Hosking DJ: Calcitonin and diphosphonate in the treatment of Paget’s disease of bone. Metab Bone Dis Rei Res 1981; 3: 317–326.CrossRefGoogle Scholar
  59. 59.
    Haddad JG, Whyte MP, Murphy WA: Human calcitonin therapy: Efficacy in Paget’s bone disease in patients with antibody resistance to heterologous calcitonins and in patients with lytic skeletal lesion. In Caniggia A (ed.): Human Calcitonin. Milan, Ciba-Geigy SpA, 1983, pp 87–93.Google Scholar
  60. 60.
    Scuro LA, Lo Cascio V, Adami S: Therapeutic use of human calcitonin in patients with Paget’s disease resistant to heterologous calcitonins. In Caniggia A (ed.): Human Calcitonin. Milan, Ciba-Geigy SpA, 1983, pp 181–191.Google Scholar
  61. 61.
    Nakada Y, Awata N, Nakamichi C, Sugimoto I: The effect of additives on the oral mucosal absorption of human calcitonin in rats. J Pharmacobiodyn 1988; 11: 395–401.PubMedCrossRefGoogle Scholar
  62. 62.
    Cho YW, Flynn M: Oral delivery of insulin. Lancet 1989; 2: 1518–1519.PubMedCrossRefGoogle Scholar
  63. 63.
    Singer FR, Villanueva R, Ginger K: Acquired resistance to salmon and human calcitonin during treatment of Paget’s disease of bone. Calcif Tissue Int 1989;44 (suppl):S-87 (N32).Google Scholar
  64. 64.
    Zanelli JM, Salmon M, Lane E, et al: Chronic treatment of rats with salmon calcitonin: A model for clinical resistance. Calcif Tissue Int 1984; 34: 480 (abstract).Google Scholar
  65. 65.
    Acezat-Mispelmer F, Boucherai M, Souchet T, et al: Evaluation of nasal tolerability of synthetic salmon calcitonin solution administered by nasal route. J Bone Min Res 1989; 4: S192 (abstract 300).Google Scholar
  66. 66.
    Miyake M, Nishihata T, Nagano A, et al: Rectal absorption of [ASU]-EEL calcitonin in rats. Chem Pharm Bull 1985; 33: 740–745.PubMedCrossRefGoogle Scholar
  67. 67.
    Thiébaud D, Burckhardt P, Jaeger P, Azria M: Effectiveness of salmon calcitonin administered as suppositories in tumor-induced hypercalcemia. Am J Med 1987; 82: 745–750.PubMedCrossRefGoogle Scholar
  68. 68.
    Nagant de Deuxchaisnes C: Development of alternative modes of administration of calcitonin, in Christiansen C, Overgaard K (eds.): Osteoporosis 1990. Copenhagen, Osteopress ApS, 1990, pp 1958–1962.Google Scholar

Copyright information

© Elsevier Science Publishing Co., Inc. 1991

Authors and Affiliations

  • Charles Nagant de Deuxchaisnes
  • Jean-Pierre Devogelaer

There are no affiliations available

Personalised recommendations